- ISIN
- US9250501064
- CUSIP
- 925050106
- Delisting Date
- Oct 8, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 27, 2017
Highlights
- Market Cap
- $9.72B
- Enterprise Value
- $9.52B
- EPS (TTM)
- -$0.69
- Total Revenue (TTM)
- $167.65M
- Gross Profit (TTM)
- $159.52M
- EBITDA (TTM)
- -$40.86M
- Year Range
- $82.88 - $106.93
- Target Price
- $145.67
- ROA (TTM)
- -11.01%
- ROE (TTM)
- -22.68%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VRNA Performance Chart
Loading charts...
Returns By Period
Verona Pharma plc
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
VRNA Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 23.39% | 21.52% | -8.82% | 13.51% | 12.67% | 16.48% | 11.11% | 0.78% | 0.76% | 0.19% | 130.21% | ||
| 2024 | -7.70% | -6.16% | -6.56% | -3.98% | -21.88% | 19.80% | 56.71% | 21.27% | 4.69% | 17.94% | 16.80% | 17.18% | 133.60% |
| 2023 | -15.65% | -2.72% | -6.34% | 4.33% | 2.72% | -1.77% | 4.49% | -12.04% | -16.11% | -14.42% | -3.08% | 47.04% | -23.92% |
| 2022 | -7.59% | -9.50% | -11.21% | -16.23% | 8.37% | -7.51% | 28.40% | 93.68% | -1.92% | 25.24% | 0.78% | 102.56% | 288.84% |
| 2021 | 12.86% | 15.57% | -8.43% | -17.70% | -12.06% | 8.10% | -3.98% | -7.32% | -5.84% | -6.57% | -6.64% | 40.59% | -4.00% |
Benchmark Metrics
Verona Pharma plc has an annualized alpha of 49.94%, beta of 1.00, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since April 27, 2017.
- This stock captured 52.36% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -67.31%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 49.94%
- Beta
- 1.00
- R²
- 0.05
- Upside Capture
- 52.36%
- Downside Capture
- -67.31%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Verona Pharma plc (VRNA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VRNA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.37 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.78 | — |
| Martin ratioReturn relative to average drawdown | — | 12.44 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Verona Pharma plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Verona Pharma plc was 89.71%, occurring on Mar 18, 2020. Recovery took 697 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -89.71%Mar 2020 | 1y 11mo | 2y 9mo | 4y 8moApr 2018 - Dec 2022 |
2024 bear market2024 | -56.07%May 2024 | 1y 4mo | 2mo 15d | 1y 7moJan 2023 - Aug 2024 |
2017 bear market2017 | -36.28%Nov 2017 | 2mo 10d | 3mo 24d | 6mo 4dSep 2017 - Mar 2018 |
2017 bear market2017 | -29.89%Jun 2017 | 1mo 5d | 2mo 11d | 3mo 16dMay 2017 - Sep 2017 |
2025 selloff2025 | -22.59%Apr 2025 | 1mo 2d | 25d | 1mo 27dMar 2025 - Apr 2025 |
Drawdown Indicators
| VRNA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -1.80% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.71% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.03% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Verona Pharma plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Verona Pharma plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VRNA relative to other companies in the Biotechnology industry. Currently, VRNA has a P/S ratio of 58.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VRNA in comparison with other companies in the Biotechnology industry. Currently, VRNA has a P/B value of 34.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VRNA
Add Verona Pharma plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VRNA